We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App





Study Questions Popular COVID-19 Test and Proposes New Marker of Disease Severity

By LabMedica International staff writers
Posted on 08 Oct 2021
Print article
Illustration
Illustration

Researchers studying the immune response to COVID-19 in patients with different levels of disease severity have found that half of the patients without symptoms did not actually produce significant amounts of IgG antibodies of a kind targeted by many popular test kits.

Nevertheless, the study by researchers at the Skolkovo Institute of Science and Technology (Moscow, Russia) found that nearly all patients produced another kind of antibodies, whose count was sometimes even higher in asymptomatic cases, leading the researchers to suggest the ratio between the two counts as an indicator of disease severity.

Blood tests for detecting prior infection with the coronavirus rely on antibodies called immunoglobulins G. IgGs usually develop a few weeks after infection and come in multiple varieties, depending on which part of the virus they attach to. Two common kinds are the antibodies targeting the nucleocapsid protein and the receptor-binding domain, or RBD, of the spike protein of the coronavirus. According to the new study, the levels of these two antibodies in patients at various times following recovery from COVID-19. It accounts for mild and asymptomatic cases, as well as serious ones.

The researchers believe that it might therefore be more reasonable to check the level of antibodies to RBD to determine if a person has had the infection. But why would it ever be the case that someone has IgGs to RBD but not to the nucleocapsid protein? This might have to do with whether the antibody in question targets the inside or the outside of the virus particle. The team hypothesizes that if a patient is having an asymptomatic case of COVID-19, their immunity must have done such a great job warding off the infection early on that the virus did not really have a chance to enter the phase of active reproduction. That stage involves cells ripping apart, with unassembled viral spare parts flying every which way. It is only in this tougher scenario that antibodies to the internal parts of the virus - such as its nucleocapsid protein - can form. But as long as the virus does not penetrate into the cell, only antibodies to RBD are produced, since they are the ones targeting the virus’s exterior.

Anti-RBD antibodies are often described as “neutralizing” since they can prevent the binding of the viral spike protein with the receptor it seeks to attach to. Indeed, the researchers showed that the amount of anti-RBD IgG correlated with the serum capacity to inhibit the RBD-receptor interaction. Intriguingly, the team found RBD levels not just to persist but to exhibit an average increase in the sample studied. According to the researchers, while this finding may seem to contradict some earlier studies that reported the concentration of antibodies to RBD falling with time, this might actually depend on what the patients in the respective samples have been up to following their recovery.

Based on the different dynamics of the two kinds of IgG antibodies, the team suggested that the ratio between their counts could serve as a marker of disease severity. For those vaccinated, elevated anti-RBD levels can indicate that the patient has already encountered the virus after getting the shot and is therefore in no need of revaccination, because a more recent immune response has occurred. The study addresses one of the gaps in the reports on the immune response of COVID-19 patients: With patients experiencing milder symptoms often not seeking medical attention, they inevitably become underrepresented in the research.

“Our main finding is that asymptomatic COVID-19 patients often have no IgG antibodies to an internal component of the virus known as the nucleocapsid protein. Yet tests detecting that very kind of antibodies are often recommended to check whether someone has had COVID-19,” said Maria Tutukina of Skoltech, the Institute of Cell Biophysics and the Institute for Information Transmission Problems of RAS.

“But regardless of disease severity, every patient we tested but one exhibited IgG antibodies to the RBD of the spike protein, which is located on the surface of the viral particle,” added study co-author Anna Kaznadzey of IITP RAS and VirIntel who also participated in the research. “It seems reasonable to expect that a patient who has recovered from COVID-19 will experience a surge of antibodies when re-exposed to the pathogen. I mean, that’s how immunity works: It is not some kind of a protective bubble you carry around. It is rather the potential to fight back against the virus effectively, should it find its way into the body again. Whether it does, and how often, might affect the subsequent dynamics of the antibody count.”

Related Links:
Skolkovo Institute of Science and Technology

Gold Supplier
SARS-CoV-2 IGRA
SARS-CoV-2 IGRA
New
Gold Supplier
Fully Automated Batch Immunoanalyzer
Evidence+
New
Laboratory Automation System
UniVerse
New
Cardiovascular Disease POC Analyzer
cobas h 232 POC System

Print article

Channels

Clinical Chem.

view channel
Image: Simoa is an ultra-sensitive immunoassay technology that allow detection of proteins and nucleic acids at lowest possible levels (Photo courtesy of Quanterix)

Plasma Amyloid-β 42/40 Assays Compared in Alzheimer Disease

Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of... Read more

Molecular Diagnostics

view channel
Image: The QuikRead go iFOBT is an immunochemical fecal immunochemical test for detection and quantification of human hemoglobin in feces in case of suspected bleeding from the lower gastrointestinal tract (Photo courtesy of Aidian)

Fecal Immunochemical Tubes Sourced to Analyze Gut Microbiome for CRC

Colorectal cancer (CRC) is a challenging public health problem which successful treatment depends on the stage at diagnosis. Recently, CRC-specific microbiome signatures have been proposed as a marker... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with peripheral T-cell lymphoma (Photo courtesy of Peter Maslak, MD)

Mutation Analysis Links Angioimmunoblastic T-Cell Lymphoma to Clonal Hematopoiesis

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid tumors and encompass peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and... Read more

Immunology

view channel
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Biosciences)

Highly Multiplexed Cell Surface Protein Analyzed Via Flow Cytometry

Modern immunologic studies increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. One of the cornerstones... Read more

Pathology

view channel
Image: Characteristic bronchoalveolar lavage findings of diffuse alveolar hemorrhage (Photo courtesy of Peter C. Bauer, MD)

Bronchoalveolar Lavage Cell Pattern Determined for Diffuse Alveolar Hemorrhage

Diffuse alveolar hemorrhage (DAH) is a clinicopathological syndrome that describes the accumulation of intra-alveolar red blood cells originating from the alveolar capillaries. DAH can induce severe respiratory... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.